Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CNBX PharmaceuticalsCNBX +33.33% Return-on-Tangible-Equity is 0.00% as of May. 2026. The stock has 3 warning signs investors should review. Among 1,198 Biotechnology companies, CNBX Pharmaceuticals ranks worse than 83472.37% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CNBX Pharmaceuticals's annualized net income for the quarter that ended in May. 2026 was $-0.62 Mil. CNBX Pharmaceuticals's average shareholder tangible equity for the quarter that ended in May. 2026 was $-2.60 Mil. Therefore, CNBX Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in May. 2026 was N/A%.
The historical rank and industry rank for CNBX Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, CNBX Pharmaceuticals's highest Return-on-Tangible-Equity was 16.75%. The lowest was -5,048.28%. And the median was -145.87%.
CNBX's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -41.64 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
CNBX Pharmaceuticals Return-on-Tangible-Equity Related Terms
CNBX Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for CNBX Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNBX vs SIGY, LIPO, CARM: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, CNBX Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CNBX Pharmaceuticals Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where CNBX Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (May. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
CNBX Pharmaceuticals (CNBX) has a Return-on-Tangible-Equity of 0.00% as of May. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CNBX Pharmaceuticals and its competitors. According to the industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 1198 companies in the Biotechnology industry.
Is CNBX Pharmaceuticals' Return-on-Tangible-Equity too high?
CNBX Pharmaceuticals' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, CNBX Pharmaceuticals ranks #999999 out of 1198 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CNBX Pharmaceuticals' Return-on-Tangible-Equity compare to SIGY and LIPO?
According to the Biotechnology industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 1198 companies for Return-on-Tangible-Equity. This places CNBX Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current Return-on-Tangible-Equity is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNBX has been successfully added to your 
